Breaking News

Jade Biosciences Closes $80M Financing

Funding will support Jade's plans to develop targeted therapies for indications with high unmet need across inflammation and immunology.

Author Image

By: Charlie Sternberg

Associate Editor

Jade Biosciences Inc., a biotechnology company dedicated to developing therapies for patients living with autoimmune diseases, has closed an $80 million financing led by Fairmount and Venrock Healthcare Capital Partners with participation by Deep Track Capital, Driehaus Capital Management, Franklin Templeton, RTW Investments, and Braidwell LP.   The funding will support Jade’s plans to develop targeted therapies for indications with high unmet need across inflammation and immunology.   ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters